JNCE News and Press, Jounce Therapeutics Inc. From 07/07/21

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Office...

- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021- - Introduction of two additional LILRB family targets as potential development candidates - -...

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it will host a virtual R&D Day at 10:00 a.m. –...

Investors were pleased with biotech Jounce Therapeutics (NASDAQ: JNCE) on Tuesday. So much so, that at one point they traded the stock nearly 21% higher on the day; ultimately it cooled down, but still closed the day 8% higher. The FDA cleared Jounce's Investigational New Drug (...

Jounce Therapeutics (JNCE) announces the triggering of a $25M milestone payment in relation to the company's agreement with Gilead Sciences (GILD).Shares up more than 10% premarket.The milestone was reached after the the U.S. FDA cleared the Investigational New Drug ((IND)...

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and Drug Administration’s (FDA) cle...

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and ...

- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas - - SELECT TIS vopra positivity rate for patient selection in-line with projectio...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Jounce Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation